drugset / Trial / NCT06440902

Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA

NCT06440902 ↗

Phase 2 Recruiting 1100 enrolled Fudan University
NaSingle-groupOpen-labelDiagnostic

Summary

Following systemic therapy in metastatic colorectal cancer(mCRC),RAS (including KRAS, NRAS and HRAS gene) status may change from a mutant(MT) to a wild-type(WT),a phenomenon known as "NeoRAS WT"mCRC.NeoRAS WT can be detected by longitudinal circulating tumor DNA(ctDNA) analysis.Therefore, this prospective phase II Study was design to explore the detection rate of peripheral blood ctDNA testing for NeoRAS WT and its guiding value for subsequent treatment for mCRC.

Timeline

Start
2023-12-28
Primary completion
2028-09-01
Completion
2028-09-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Cetuximab Monoclonal antibody — —

Indications